From The Economic Times · Rica Bhattacharyya · · 1m 10s
Zydus Targets New Growth Areas
Zydus Lifesciences plans to expand into specialty medicines and biologics while maintaining US generics.
In brief
Zydus Lifesciences plans to expand into specialty medicines and biologics while maintaining US generics. Zydus Lifesciences will grow through specialty medicines, biologics, and US generics while targeting 18-20% market share for saroglitazar. Originally reported by The Economic Times.
Zydus Growth Strategy
Zydus Lifesciences aims to expand beyond traditional pharmaceuticals into specialty medicines and biologics.
“The focus is to build capabilities beyond traditional pharmaceuticals”
Specialty Focus
The company targets liver care, nephrology, and cardio in India with new therapeutic areas.
“In india, we want to be a very strong player in liver care”
Saroglitazar Launch
Saroglitazar aims for 18-20% US market share as Zydus enters specialty drugs.
“We are looking to target a 18-20% share of prescriptions in the us market”
Oncology Expansion
Zydus is the only Indian oncology company in the top three in the local market.
“We are the only indian oncology company in the top three in the local market”
US Generics Engine
US generics remain Zydus' largest market with room for growth.
“Us generics is still our largest market and still offers room to grow”
CAR-T Therapy
Zydus has built CAR-T therapy capabilities for next-generation treatments.
“Now we have car-t chimeric antigen receptor t-cell therapy capability”
GLP-1 Market
Oral GLP-1 drugs may dominate the diabetes market in the long term.
“In the long term, with the new molecules, i think orals will play a bigger role than injectables”
Profitability Targets
Zydus expects 24% Ebitda with improved profitability over the next five years.
“We are at around 24% ebitda and we hope to continue to improve in the next five years”
Chinese Partnerships
Zydus plans to license novel biologics from Chinese companies for unmet needs in India.
“We will also look to license for unmet needs in india for novel biologics from china”
Next Phase
Zydus will focus on specialty medicines, biologics, and US generics for sustained growth.
“We are gearing up for its next phase of growth, placing new bets on specialty medicines, complex biologics, innovative products, medical devices, and contract development and manufacturing”
The short version
Zydus Lifesciences will grow through specialty medicines, biologics, and US generics while targeting 18-20% market share for saroglitazar.
